lamivudine / zidovudine
This is a summary of the European Public Assessment Report (EPAR) for Combivir. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Combivir.
For practical information about using Combivir, patients should read the package leaflet or contact their doctor or pharmacist.
Combivir : EPAR - Summary for the public (PDF/92.8 KB)
First published: 25/09/2008
Last updated: 01/02/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
ViiV Healthcare BV
|Date of issue of marketing authorisation valid throughout the European Union||
Van Asch van Wijckstraat 55H
11/08/2022 Combivir - EMEA/H/C/000190 - IG1532
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antivirals for systemic use
Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.